These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7773185)

  • 1. Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation.
    Dahiya R; Zhang DY; Ho RJ; Haughney PC; Hayward SW; Cunha GR; Narayan P
    Biochem Mol Biol Int; 1995 Mar; 35(3):487-98. PubMed ID: 7773185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S; Kraft AS
    Cancer Res; 1998 Feb; 58(4):834-9. PubMed ID: 9485043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells.
    Dahiya R; Boyle B; Park HD; Kurhanewicz J; Macdonald JM; Narayan P
    Biochem Mol Biol Int; 1994 Jan; 32(1):1-12. PubMed ID: 8012274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
    Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
    Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
    DeMiguel F; Lee SO; Lou W; Xiao X; Pflug BR; Nelson JB; Gao AC
    Prostate; 2002 Jul; 52(2):123-9. PubMed ID: 12111703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
    Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
    Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.
    Tuxhorn JA; McAlhany SJ; Dang TD; Ayala GE; Rowley DR
    Cancer Res; 2002 Jun; 62(11):3298-307. PubMed ID: 12036948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
    Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
    Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
    J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
    Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.